Skip to main content

WELCOME

CAMP PODS is a webinar series, consisting of nine one-hour sessions that will take place from February to November 2024 on the 1st Thursday of each month.

The goal of this series is to build a strong Oncology Laboratory Medicine community, where best practices and common challenges can be discussed.  Insights gained will be key to implement across Canada and will help streamline laboratory workflows and practice for laboratory medicine, the end result of which will be improvements in the patient journey.

Overall Learning Objectives:

By the end of the webinar series, an audience member will:

  1. Establish a strong Oncology Education Network
  2. Compare ideas, thoughts and common challenges
  3. Identify gaps and find team solutions for improving patient care
  4. Integrate pathology and oncology practices

OUR NEXT CAMP PODS SESSION – POSTPONED

Thursday, August 1st, 2024
10:00am – 10:45am PST MMR testing in colorectal cancer
Diagnostic and interpretation challenges
Testing pitfalls
Esmeralda Celia Marginean, MD, FCAP, FRCPC
Professor of Pathology, Baylor College of Medicine
Houston, Texas
10:45am  – 11:00am PST Questions & Answers
Learning objectives:
By the end of this presentation, participants will be:
1. Familiar with the main CRC molecular pathways
2. Aware of whom to test for MMR and what type of tissue to test
3. How to interpret and report MMR test results in CRC
4. Be aware of MMR IHC testing/interpretation pitfalls
5. Troubleshoot IHC staining

OUR LAST CAMP PODS SESSION

Thursday, May 2nd, 2024
10:00am – 10:45am PST Molecular Insights Impacting Salivary Gland Tumor Classification Dr. Justin Bishop
Professor, Chief of Anatomic Pathology,
Jane B. and Edwin P. Jenevein M.D. Distinguished Chair in Pathology UT Southwestern Medical Center,
Dallas, Texas
10:45am  – 11:00am PST Questions & Answers
Learning Objectives:

  1. List three salivary gland tumors with defining generic alterations.
  2. Detail the reasons that salivary gland adenocarcinoma, not otherwise specified is becoming a rare diagnosis.
  3. Name two tumors in the differential diagnosis of palisading adenocarcinoma.